India Calls for Trust, Reliability and Innovation in Redesigned Global Pharma Supply Chains
Mumbai, February 23: Union Minister J P Nadda on Monday called upon India’s domestic pharmaceutical industry to take a leadership role in the evolving global supply chain by focusing not only on scale but also on quality, reliability and innovation.Addressing the 11th edition of the Global Pharmaceutical Quality Summit virtually, the Minister for Health and Family Welfare and Chemicals and Fertilizers emphasized that as global supply chains undergo restructuring, India must position itself as a trusted anchor.
“As global supply chains are redesigned, India must anchor them, not only with scale, but also with quality, reliability, and innovation. Trust will define leadership in the coming decades,” he said.
Post-COVID Supply Chain Shift Creates New Opportunities for India
In the post-COVID era and amid shifting geopolitical landscapes, global supply chains are being restructured to reduce single-source dependency. New models are emerging that promote diversified geographies and shared manufacturing responsibilities.Against this backdrop, India is seeking to strengthen its position as a dependable pharmaceutical manufacturing hub by aligning scale with global quality standards.
AI and Emerging Technologies Reshaping Indian Pharma
The minister highlighted that India is responsibly adopting emerging technologies, particularly artificial intelligence, to enhance healthcare delivery and pharmaceutical systems.Artificial intelligence is being leveraged for:
- Early disease detection
- Predictive diagnostics
- Improved healthcare outreach
From “Pharmacy of the World” to “Innovator of the World”
India has long been recognized as the “pharmacy of the world” due to its large-scale generic drug production. According to Nadda, the country is now transitioning toward becoming the “innovator of the world,” with healthcare security, manufacturing resilience and scientific excellence forming the core of national development.This shift is supported by significant policy initiatives and financial commitments aimed at strengthening research, regulatory systems and manufacturing capabilities.
Biopharma Shakti Initiative to Boost Manufacturing and Clinical Research
The Biopharma Shakti Initiative, with an outlay of Rs 10,000 crore, is designed to position India as a global biopharmaceutical manufacturing hub.The initiative aims to:
- Strengthen domestic biopharma production
- Expand research capacity
- Create over 1,000 accredited clinical trial sites
- Reinforce the Central Drugs Standard Control Organization with a scientific review cadre aligned to global standards
Rs 5,000 Crore PRIP Scheme to Drive Pharma MedTech Innovation
The Rs 5,000 crore Promotion of Research and Innovation in Pharma-MedTech Sector scheme is focused on accelerating innovation in:- New medicines
- Complex generics
- Vaccines
- Advanced medical technologies
Commitment to Regulatory Excellence and Quality-First Approach
Reaffirming India’s commitment to regulatory excellence, Nadda said the country is investing in scientific expertise, digital systems and institutional capacity to ensure predictability and alignment with global standards.He emphasized that infrastructure investments must be complemented by investments in people, systems and leadership.
“A quality-first mindset across every stage from raw material sourcing to finished product release is the only path to sustain global competitiveness,” the minister stated.
With global supply chains undergoing transformation, India’s pharmaceutical sector is positioning itself to lead through trust, innovation and regulatory strength.
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.